Numerous diseases, such as diabetes, autoimmune disorders, neurological disorder, and cancer are caused because of dysregulation of a complex interplay of genes [8] . One of the most advanced and innovative techniques used by biotechnological researchers is genomics, which incorporates genomic sequence and human genome analysis. The knowledge of genomics has empowered researchers to adopt a more represented strategy in developing safe and effective drugs. Genome sequencing can predict the risk of developing diseases, the origin, traits, and response to drugs. With profound knowledge of genomic data, organizations are currently ready to develop drugs that affect pathogens or cancer cells, without causing any harm to healthy body cells [9] . In addition, vast knowledge in genomics can proffer further ideas into the mechanism of drug action, which contributes to discovering novel therapeutic agents [10] . Furthermore, dissimilarities in the genomic makeup in humans present a surplus opening for effective drug discovery [11] , identification of target molecule, and evolving drug leads to the apt likelihood for preclinical and clinical studies [12] . The use of gene studies in the preclinical setting necessitates one to screen numerous compounds with negligible discrepancy. At the point when the target gene is isolated, the chemical that works best largely in contradiction of all its subtypes is picked for further studies [13] .

Other sources which integrate genomic data at the notch of chromosomal DNA, disease-associated genes, mRNA transcript sum up of tissues, genetic difference data in humans, and animal and developmental modes applicable to disease all embrace genomic methods [14] . For illustration, if the disease target implicates human endothelium, genomic data on the target organ context can be quarried with bioinformatics for the discovery process. The adoption of transcriptional arrays or DNA sequencing of a complementary DNA library of human endothelial cells provides a standpoint on gene transcription in the human endothelium. Likewise, proteomics can give an understanding of the useful protein in specific cells [14] .

Quite a lot of studies have proven that genomics aids majorly in the identification of drug-target processes since it is considered a high throughput screening of expressed genes. Also, the work of Zhang et al., highlighted several works of literature to show that the analysis of the genome does not account for the post-translational process, which takes account of protein amendment and protein metabolism [15] . Genomics is positioned on genetic data, while proteomics considers genetic data of DNA or mRNA, as well as protein post-translational modification. Thus, the practices involved in the discovery of drugs moved from genomics to proteomics. Yet, the discovery of molecular targets for specific diseases requires the understanding and utilization of both genomic and proteomic methods at the biochemical and physiological levels [15] .

Proteomics has attained a lot of consideration as a drug development platform [13] , the skills adopted in proteomics can give a wide-ranging evaluation of countless activities in clinical research of numerous diseases [16] . As most drugs bind to proteins or nucleic acid (enzymes, ion channels, or receptors) [17] , the proteomics model embroils trailing an unstable protein that is prompting a harmful effect, and subsequently, the application of a drug molecule to revise its effect [18] . The proteomics approach involves; 1) Target identification and validation, 2) Biomarker identification (Efficacy and safety) [19] .

The use of biotechnology in drug discovery is a broad area and yet growing and famous field [27] . Effective quality and design are implemented in biotechnological drug discovery to allow persistent drug delivery and increase drug performance [28] . In support, biotechnological production is irreversible, very luxurious, and encompasses a lot of critical parameters throughout the process. Quality control tests applied to the intermediate and final product become inefficacious; therefore, sustaining predefined quality is vibrant [27] . The quality and design implementation in biotechnological drug discovery follows four key stages: 1) define a target; 2) design the product; 3) identify potential risk, and 4) develop a control strategy [27] [29] .

Protein kinases are at present one of the most detected classes of drug targets as established by the multiple kinase inhibitors that have arrived in clinical trials in recent years [37] [40] . Imatinib, a tyrosine kinase inhibitor, is a drug that is now approved by the food and drug administration (FDA) for the treatment of specific types of cancer. As there are over 500 known human protein kinases and most of them engage in adenosine triphosphate binding pocket which is extremely sealed, selectivity is a crucial issue [37] . The main use of protein for the advances of drug compounds is to identify the structure of a protein in a complex with a tool compound such as a lead inhibitor to give a new chemical postulate to enrich inhibitor affinity by signifying new chemical reforms [41] .

The importance of complete genome sequences for modern approaches to drug discovery can never be underestimated. Researchers now understand the full match of proteins encoded by the human genome, and most human proteins can be allocated into structurally and mechanistically allied folks based on sequence homology [42] . The study of gene purpose from high throughput studies of protein-protein collaborations can be divided into networks and pathways using bioinformatics data combination tools [43] . The sequence of the genome has given a comprehensive parts list elucidating all the proteins available in the human body, and high throughput screening techniques give podia for exposing these proteins to millions of small molecules [41] . Therefore, the role of protein and genome sequences cannot be overemphasized in today’s drug discovery.

The use of in vitro models in drug development has been a foremost enhancement, not only in the innovation of essential chemical compounds, but also in providing relevant information on their pharmacodynamics i.e. “absorption, distribution, metabolism, and excretion” (ADME) features [44] . The advance of several in vitro pharmacodynamics models has prepared a resilient influence on the pathway in the route of transforming and accelerating drug discovery and development. For example, engineered tumour eternalized cells obtained from humans or animals have remained the finest acknowledged in vitro approach used by the biotechnology and pharmaceutical industries [45] [46] . Though these cell lines own the aids of aptness and scalability of the selection process, they elucidate extraordinary patchiness in their advance, strange genotype, and biological reaction to pharmaceutical formulations. However, the irregularities associated with these eternalized cells edged the rate and figure of prime molecules for drug development. Another example is the practice of dedicated basic culture approaches such as hepatocytes, human umbilical endothelial cells, and keratinocytes delivered fractional practice owing to their synchronized expandability [47] . In this case, the obligation for an enriched and constant physiological reaction, typical genotype, and development configuration has redirected drug innovation determinations near the understanding of stem cells. Furthermore, the prospect of detaching stem cells from a huge continuum of tissues [48] and evolving them in vitro, as well as their competence to ghettoize into several proficient cell types, has delivered an instrumental means for drug/target sighting and endorsement [49] . This implies that the application of stem cells does not only diminish the cost of pharmaceutical drug discovery but also upsurges the prospect of spotting primes with a target or pathway noteworthy to the disease diagnosis.

It is also important to note that stem cells from different biological components are not alike [50] , and in vitro breeding where the stem cells are delivered with growing features is different from the small environment in which stem cells exist in the living system [51] . This means that stem cells have a more lethargic cell progression than their precursor cells in vivo, so the grade of the warmth of details resultant in a test tube or dish may vary from that of the living system [52] .

The use of the principle of mathematics and computer science application in biology has proven effective over the years, thereby triggering the expansion of the use of in silico approach. In silico (commonly called bioinformatics) denotes the use of computers or computer simulations to perform biological findings. Its practicality in biomedical sciences has additional worth to drug discovery study at the biotic level [53] [54] . Consequently, the computer approach is significant in cogent drug formulation, which principally depends on the prevailing biotic and pharmaceutical properties of ligands [55] . A sequence of ligands by such assets is vetted for the variety of the most feasible candidates. In silico approach is computer-based on the in vivo technique and their understanding is based on both mathematics and computations. In these techniques, mathematical means can be adopted to outline the integer of drug recipes in data screening, this will diminish the amount of pilot investigation in the order of tens of thousands of likely alignments. The result may perhaps be subjugated to the proof of identity of a prosperous drove-out drug amalgamation and the foremost syndrome subsidizing pathways. Computational scrutiny can now examine the amalgamated structures accompanying the host mechanisms, consistently the pathological pathways, to reserve therapeutic methods using equivalent models. A simulation is then run to definite considerations such as competencies, toxicities, and other side effects of the drugs in the handling of diseases from a system perception [56] .

Typical illustrations are selection models called medicinal algorithmic combinational screens, and measurable confirmation action affiliation of herbal formulae. In this method, the network-constructed biological computational approach is smeared by mathematical models demonstrating the biological pathways which govern the sophisticated level of cellular special effects in multi- target drugs. Also, the unified network target-based identification of the multicomponent synergy model, which relates drugs to their molecular targets [57] , emphasizes its presentation as a data-modeling practice.

The efficacy of the in-silico techniques has auxiliary enriched the recognition of the hazardous properties of drug substances [58] . The in silico system has also lengthy the prospects of drug repurposing by combined networks [59] [60] . This routine scrutinizes the genomic dissimilarities that give to different reactions to drugs for precision medicine use and the forecast of disease proneness [61] .

There are different approaches to in silico model of drug discovery, among which are genomics, proteomics, metabolomics, and much more with the most prominent one being molecular docking. Molecular docking is the use of the computational model for the prediction of ligands-target confirmation; of which ligands can be a small molecule or peptide synthesis from either plant, microbes, or animal while the target can be a protein or nucleic acid whose activity is paramount for the survival of a disease with having beneficial effect to the host or not evenly distributed throughout the living system. Although, because of the advances in silico analysis of drugs, several web servers are employed for the prediction of pharmacokinetics and drug-likeness proprietaries of a potential therapeutic agent. Also, a process called molecular dynamic stimulation is also employed to determine the selectivity and absorption potential of a promising drug candidate. Figure 2 denotes the process involved in molecular docking, and Table 2 gives a general overview of these techniques and their applications in drug discovery.

Chemical similarity is a key perception in drug development that is utilized to invent compounds with comparable bioactivities centered on structural resemblances between two ligands [74] . A drug designer can build a series of structural

equivalents with superior pharmacological characteristics when a prime compound is revealed using a chemical screen. The chemical correspondence concept, which holds that if two compounds have analogous structures, they are probable to have equivalent bioactivities, is at the core of similarity-based drug discovery. While there are exceptions, the relationship between chemical structure and compound activity in medicinal chemistry is well known [75] . Consequently, the causal structural similarity between two compounds is a prerequisite aimed at match-built drug discovery. A visual inspection can quickly determine the similarity between two ligands at a basic level by finding shared practical groups, structural motifs, or substructures. On the other hand, human involvement is frequently subjective and unsuitable for large-scale examination. Therefore, a successful drug discovery exertion necessitates the use of computational methods for unprejudiced chemical connection assessment and a thorough database [76] .

More than a few computational chemical relationship search performances have been developed [74] [75] [76] . Chemical infrastructure impressions are the most often exploited method. By drawing common chemical motifs into twofold arrays known as structural keys, non-hashed structural fingerprints such as molecular access system (MACCS) keys or open babel fingerprints detect predetermined substructures or functional group patterns in a molecule. Each fragment is turned into a dualistic sequence of 0 and 1, representing the existence or absence of a precise substructure, to relate chemical relationships between two molecules. Chemical-muddled patterns, such as daylight fingerprints on the other hand, utilize paths in their hashing [74] .

The next step is to use a distance metric to measure chemical similarity when the chemical fingerprints have been resolute in a chemical hunt and the particles have been interpreted to acceptable data demonstrations. Some of the common distance measurements frequently used in chemoinformatics and bioinformatics to achieve this are Euclidean, and Mahalanobis metrics [77] . On the other hand, the Tanimoto index is the simplest and most direct distance metric in the instance of dual chemical impressions. In the range of 0 - 1, Tanimoto metrics compute the element of mutual bits among chemical prints. Even though there is no common Tanimoto index cutoff (Tc) for determining whether double fragments are satisfactorily alike, most chemical searches should begin with a Tc value of 0.7. Alternatively, depending on the total Tc score distribution, statistical metrics such as a Z-score can be generated [76] .

In addition, 3-dimensional chemical similarities prints have been engendered in addition to 2D prints. For structural correspondence assessment, 3D chemical connection patterns use 3D structural evidence from ligands such as molecular shape, pharmacophore points, or molecular interaction fields [75] . Even if 3D chemical match evaluations may stereotypically capture fundamental characteristics important for protein-ligand interaction, 3D arrangement systems are computationally expensive and often demand considerable optimization techniques to augment the coincided volume. Nonalignment approaches established on chemical descriptors such as GETAWAY or 3D-MoRSE descriptors, on the other hand, can be employed [78] . The 3D chemical descriptor can capture 3D ligand properties from 2D data, potentially reducing computing time. To prove 3D structural similarity, however, extensive post-validation may be required [77] .

In the era of big data, the integration of artificial intelligence (AI) with biotechnology in drug discovery holds great promise [79] . By harnessing AI, hidden or meaningful patterns and relationships within complex biological systems can be discovered [80] . This will facilitate the analysis of genomic and proteomic data, enabling the identification of new therapeutic targets and the design of more effective drugs [81] . Through AI-driven predictive modeling, machine learning (ML) algorithms can be leveraged to analyze existing data on drug-target interactions, chemical structures, and biological activities. AI algorithms can also be utilized in two key areas: natural language processing (NLP) and virtual screening. In the context of NLP, AI algorithms can process and extract information from vast databases [82] . Additionally, AI algorithms can be employed in virtual screening to screen large databases of compounds [83] . This can help identify potential compounds that exhibit a high affinity for specific therapeutic targets. These analyses will help optimize drug design and the prediction of safe and therapeutically efficacious compounds. Embracing AI in biotechnology represents a transformative approach that accelerates the discovery of innovative therapeutic agents, providing researchers with powerful tools for precise and personalized treatment options.